Renovaro Biosciences
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $81,639,296.
Profit Margin
| 2014 | 0 | -2.37M | |
|---|---|---|---|
| 2016 | 42.76K | -1.73M | -4057.24% |
| 2018 | 0 | -6.31M | |
| 2021 | 0 | -26.72M | |
| 2024 | 0 | -80.65M |
RENB Income Statement (2014 – 2023)
| 2023 | 2020 | 2017 | 2015 | 2014 | |
|---|---|---|---|---|---|
Revenue | |||||
Revenue | 0 | 0 | 0 | 42.76K | 0 |
Cost of revenue | 121.85K | 391.41K | 18.48K | 32.66K | 314.64K |
Gross profit | -121.85K | -391.41K | -18.48K | 10.1K | -314.64K |
Operating exp. | |||||
Research and development | 2.70M | 15.72M | 616.96K | 804.18K | 0 |
Selling and marketing | 383.54K | 0 | 0 | 0 | 0 |
Total operating expenses | 81.63M | 23.40M | 3.21M | 2.13M | 2.11M |
Operating income | -81.63M | -23.40M | -3.23M | -2.12M | -2.42M |
Other income (expenses), net | 989.12K | -3.44M | -3.18M | -77.09K | -119.19K |
Income before tax | -80.65M | -26.84M | -6.42M | -2.19M | -2.54M |
Income tax expense | 0 | -125.27K | -111.71K | -462.78K | -177.53K |
Net income | -80.65M | -26.72M | -6.31M | -1.73M | -2.37M |
Earnings per share | |||||
Basic EPS | -0.84 | -0.57 | -0.29 | -0.18 | -0.32 |
Diluted EPS | -0.84 | -0.57 | -0.29 | -0.18 | -0.32 |
| Data source |